Home >> Competitive Intelligence >> Go-To-Market-Strategy >> Case Studies
LITERATURE ANALYSIS

Evidence-Based Risk Profiling for
Sema3A Pharmacological Inhibition

The UK R&D team of a multinational pharmaceutical company leveraged our literature analysis to evaluate the safety profile of Sema3A inhibition. The strategic guidance provided by our team enabled the identification of critical organ-specific hazards, streamlining preclinical R&D timelines and empowering high-confidence go / no-go decisions across their drug development pipeline

Let's Talk
The Challenge

Bridging Knowledge Gaps Pertaining to Sema3A Inhibitors for Precise
Pharmacological Risk Assessment

Fragmented Sema3A
Literature

The client faced significant hurdles in synthesizing scattered global publications, making it difficult to form a cohesive risk profile for Sema3A inhibition

Inconsistent Hazard
Evidence

Inconsistent data, ranging from high-level knockout mice studies to preliminary cell culture experiments obscured the true potential for organ-specific hazards

Complex Parameter
Mapping

Due to lack of structured information across organ systems, species and investigation methods, the team failed to perform a reliable, evidence-based risk evaluation

The Roots Way

How Roots Helped?

Roots Analysis collaborated closely with the UK R&D team to deliver a structured literature analysis. We systematically addressed their risk assessment needs through the following approach:
Literature Screening: We conducted a targeted literature search across central publication databases using precise keywords and identified nearly 1,100 articles from the past five years. These were then screened to identify the specific articles that were relevant to the scope of the project.
Data Extraction: We systematically extracted data from the refined dataset across various parameters, such as target indication, type of target organ system, experimental system, species, method of investigation and the role of Sema3A in different organ systems.
Evidence-based Risk Assessment: We analyzed the final dataset based on the aforementioned parameters to derive actionable insights, highlighting the potential risks of Sema3A pharmacological inhibition in specific organ systems. We delivered comprehensive visualizations and stratified summaries, ranking the level of evidence to support strategic go / no-go decisions.
Change We Created

Results You Can Quantify & Impact
Our Clients Can Count On

65%
Time Saving:
Reduced literature review timelines from months to weeks, allowing the R&D team to pivot quickly based on curated data
4
Critical Risks Identified:
Critical organ-specific hazards surfaced across kidney, immune and neural systems, guiding safer inhibitor design and target deprioritization
2x
Increase in Decision Confidence:
Provided an evidence-based framework that minimized uncertainty in preclinical stages, preventing resource waste on high-risk pathways

Want to Start?

READ MORE CASE STUDIES

Explore How We Helped Others